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Introduction
Acute kidney injury (AKI) following elective, non-cardiac surgery is increasingly recognised as an important postoperative complication. A recent meta-analysis demonstrated that one in six patients undergoing major abdominal surgery suffer AKI [1] . Despite most AKI being classified as 'mild' (a small increase in serum creatinine level, and returning to pre-operative baseline), sustaining AKI postoperatively is associated with a 12-fold increase in the unadjusted risk of in-hospital mortality and a three-fold increase in one-year mortality [1] [2] [3] . There is concern that the stress response to surgery, which typically lowers serum creatinine in its early anabolic phase, may be masking the true severity of postoperative AKI, and overestimating renal recovery. In severe AKI, its impact is more apparent, when temporary renal replacement therapy may be required.
The development of AKI following elective surgery is a multifactorial process. Induction of general anaesthesia, intra-operative fluid depletion (including bleeding), systemic inflammatory responses and insensible fluid losses all contribute towards a reduction in end-organ perfusion and subsequent renal injury [2] . Nephrotoxic drugs and intravenous contrast dyes are also used commonly in the peri-operative setting, with risk of interstitial nephritis and acute tubular damage. Patient comorbidities, particularly cardiovascular disease, chronic renal disease and renal artery stenosis, further increase the risk of AKI in this cohort [3, 4] . Concerns exist regarding the mechanism of action of commonly used antihypertensive drugs and the risk of postoperative AKI [5] . Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-2 receptor blockers (ARBs) may increase the risk of AKI through a range of mechanisms, including systemic hypotension, renal artery constriction and interstitial nephritis [6] . Withholding these agents in the peri-operative period may be an effective means of reducing the burden of postoperative AKI.
When multiple antihypertensive drugs are used concurrently, the risk of AKI may be even more significant [7] . In patients aged < 55 years, ACEi or ARBs are recommended as first-line treatment of hypertension before elective surgery [8] and offer long-term benefits to patients with significant cardiovascular and renal disease [9] . In patients with chronic kidney disease (CKD) and diabetes, ACEi/ARBs are recommended by the National Institute of Health and Care Excellence, due to their renoprotective effect [10, 11] .
In cardiac surgery, the peri-operative administration of ACEi/ ARBs has been associated with a lower-risk of AKI [12, 13] .
There is currently a paucity of data to support the routine continuation or withholding of ACEi/ARBs peri-operatively in non-cardiac surgery, with no large cohort or randomised studies examining the impact on the incidence of AKI.
This study aimed to identify whether withholding ACEi/ARBs pre-operatively reduces the incidence of postoperative AKI following major, elective gastro-intestinal and liver surgery.
Methods
In this prospective, observational, multicentre study, data were collected from patients undergoing elective gastrointestinal or liver surgery between 23 September and 18 November 2015. Any hospital in the UK and Republic of Ireland providing elective surgery was eligible to participate. Data were collected according to a previously published study protocol [14] . A UK research ethics committee determined that this project did not require ethical approval as the variables collected were routine clinical data and no change or intervention was made to patient care. However, each participating centre was responsible for local registration of the study as service evaluation/clinical audit and gaining Caldicott guardian approval. Data were collected across a collaborative student audit and research network, which has been described previously [14] . Briefly, data collection in each unit was performed by teams consisting of two to three medical students, with a supervising junior doctor and consultant providing oversight and guidance. This study is reported according to STROBE guidelines [15] .
Each participating centre collected data on consecutive patients during predefined two-week intervals. Con- The primary outcome of this study was the incidence of AKI within seven days of surgery. The Kidney Disease Improving Global Outcomes (KDIGO) serum creatininebased criteria for AKI were used (26.5 lmol.l À1 rise in serum creatinine within 48 h or > 50% rise in serum creatinine within seven days) [16] . Serial measurements were used to calculate increases in serum creatinine.
Since urine output is often measured and documented poorly, the KDIGO urine output criteria for AKI were not To analyse the association between the perioperative use of ACEi/ARBs and the incidence of postoperative AKI, patients taking ACEi/ARB preoperatively were classified into two cohorts: 1. ACEi/ARBs therapy continued peri-operatively; and 2. ACEi/ARB medication withheld ≥ 24 h before surgery.
The peri-operative administration of other medications was defined within the study protocol [14] . For diuretics, all loop, thiazide, thiazide-like and potassiumsparing diuretics were considered together and could have been administered before or after the operation. [17] . This was then equated to a pre-operative CKD stage using the KDIGO classification [16] .
Local investigators uploaded data to a secure online website, provided using the Research Electronic Data Capture (REDCap) system [18] . The submitted data were checked centrally. Investigators who submitted entries with incomplete or incorrect data were contacted to ensure data integrity. Where data were missing over 5% of predictor variables, it was intended to impute this using a Markov chain Monte Carlo multiple imputation approach. Before undertaking the study, collaborators were invited to investigator meetings and required to complete training modules on outcome assessment and data security. On completion of the study, data points were validated for accuracy and case ascertainment by investigators who were independent from the teams collecting data at each centre. Data accuracy was calculated by the number of correct individual data fields per centre divided by the total number of data points collected at that given centre.
Case ascertainment was calculated by dividing the number of correctly included cases by the number of cases eligible for inclusion within the given data collection period.
There is a paucity of high-quality non-randomised data on the effects of ACEi/ARB on the incidence of AKI, which thus precluded formal sample size calculation. We hypothesised 12% of patients would develop AKI postoperatively and that withholding ACEi/ARBs would be associated with an absolute risk reduction of 7%. Given these assumptions, we required 332 patients in each group, given a power of 0.90 and a two-sided a of 0.05, with an allocation ratio of 1:1.
Due to the influence of selection bias on patients receiving ACEi/ARBs and cardiovascular risk factors, careful adjustment for these factors was required. Baseline characteristics and outcome data were summarised using basic counts and percentages to create summary tables.
Testing between treatment groups in summary tables was done using the Chi-squared test, or in the case of continu- Once the propensity-matched models had been designed to consider clinically-relevant variables, they were checked for balance using univariable statistical comparison.
Propensity models were then rebalanced to account for any variables which were not accounted for adequately on the initial match. We also adjusted for confounding factors in subsequent logistic regression models used on the matched data. This is known as a 'doubly robust' approach as it combines two methods to reduce the effects of selection bias and is less sensitive to mis-specification. All second-order interactions were explored using multiplicative models. Model fit was guided using the Akaike informa- 
Results
Over the study period, 949 patients undergoing elective surgery on ACEi/ARB therapy were included from 160 centres in the UK and Republic of Ireland (Fig. 1 ). This was a planned subset analysis of a prospective cohort study investigating the incidence of AKI after surgery [14] . In this study, 949 out of 4423 patients (21.5%) were prescribed ACEi/ARBs before admission (Fig. 1.) . Out of 4423 patients, ACEi/ARB prescription data were missing for 37 (0.8%). Independent validation of 12,096 data points from 1008 patients from the study that these data were obtained from, demonstrated the data accuracy to be 98.0%, with a case ascertainment rate of 92.2%.
Baseline data were similar for the two study cohorts (Table 1) .
Patients who had their ACEi/ARBs therapy continued peri-operatively did not have a higher incidence of postoperative AKI compared with those who had these drugs withheld (68 (18.1%) vs. 107 (18.7%), respectively; p = 0.914). Furthermore, for patients who did sustain AKI, this was comparable in severity across both study cohorts (Table 2) . At the univariable level, withholding ACEi/ARBs over the peri-operative period was not associated with a reduction in risk of AKI ( a propensity score matching algorithm. After the matching algorithm was applied there were no significant differences between cohorts (see Appendix S1). After propensity score matching, the lack of observed effect between withholding ACEi/ARB therapy and AKI remained ( Table 4 ).
There was no significant difference between 30-day mortality and requirement for renal replacement therapy between the study cohorts. At the univariable level, there were no associations between withholding ACEi/ARBs and postoperative mortality at 30 days (Table 5 ). When this was adjusted for the effects of explanatory variable, there remained no association between withholding ACEi/ARBs and the risk of death within 30 postoperative days ( Table 5 ).
Discussion
This large, prospective study found that withholding ACEi/ARB therapy peri-operatively was not associated with a lower incidence of AKI after major, non-cardiac surgery. When we accounted for the use of other medica- [4, 22] .
A recent large cohort study [19] has investigated the use of ACEi/ARBs peri-operatively and found that withholding ACEi/ARBs for 24 h before non-cardiac surgery [19, 24] . Despite these shortcomings, studies have found that patients on long-term ACEi/ ARB therapy were more likely to have episodes of postinduction hypotension and require inotropic support intra-operatively [22] [23] [24] . Conversely, in cardiothoracic surgery, the use of ACEi/ARBs has been shown to decrease the rate of postoperative atrial fibrillation and has been implicated with a reduction in postoperative cardiovascular events, although this remains controversial [12] . At present, there are randomised trials underway in orthopaedics and cardiac surgery which will contribute to the ongoing debate [25] [26] [27] .
A key strength of our study is the use of accurate, validated data from a prospective, multicentre cohort study. In this context, it makes the findings widely generalisable. Collection of prospective data on patients undergoing major gastro-intestinal surgery allowed for creatinine levels to be recorded to detect AKI according to the KDIGO classification [16] , although this should be considered with the caveat that collection of the urine output criteria was not feasible. This clear and objective outcome assessment enabled this study to identify a higher incidence of AKI than previously reported in other studies [2, 28, 29] . Furthermore, this study collected data on other variables thought to contribute towards AKI (including medications), which enabled us to explore multiple variables as opposed to ACEi/ARBs use in isolation.
Our study has several limitations to consider. As an observational study, it is subject to selection bias. We attempted to minimise this through careful riskadjustment and using methods for causal inference to provide a robust sensitivity analysis. It is important to con- factor for AKI, and patients undergoing major gastrointestinal surgery may potentially experience substantial physiological disturbance to their volaemic status. Other factors include the presence of intra-and postoperative hypotension, which would impact upon renal perfusion.
We did not collect haemodynamic or fluid balance data, as these are complex and intrinsically linked factors which have been studied in depth already [22] . Nevertheless, these factors may have influenced our study's findings. Our study relied on routinely collected blood samples for the measurement of serum creatinine. It is possible that some patients may have had a rise in creatinine which was undetected by routine sampling; therefore, we propose the incidence of AKI in this study is a conservative estimate. Furthermore, our study may have underestimated the incidence of AKI due to excluding the KDIGO urine output criteria for AKI diagnosis.
This study is the largest of its type investigating the effects of withholding ACEi/ARB therapy during the peri-operative period in major elective, non-cardiac surgical patients. Our data do not show that the routine withholding of ACEi/ARBs in peri-operative setting has any impact on the incidence of postoperative AKI. Policymakers should consider pursuing a definitive answer to the research question through a well-conducted, randomised trial.
